
Solara Active Pharma (SOLARAPP) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
3.2B
Gross Profit
1.7B
54.11%
Operating Income
334.4M
10.48%
Net Income
105.2M
3.30%
EPS (Diluted)
₹2.46
Balance Sheet Metrics
Total Assets
22.3B
Total Liabilities
11.3B
Shareholders Equity
11.0B
Debt to Equity
1.03
Cash Flow Metrics
Revenue & Profitability Trend
Solara Active Pharma Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 12.8B | 12.4B | 13.8B | 12.3B | 15.8B |
Cost of Goods Sold | 6.3B | 8.4B | 8.1B | 6.8B | 7.5B |
Gross Profit | 6.6B | 4.0B | 5.7B | 5.5B | 8.2B |
Gross Margin % | 51.2% | 32.3% | 41.0% | 44.6% | 52.2% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 585.1M | 553.3M | 650.5M | 648.0M |
Other Operating Expenses | 2.4B | 2.4B | 2.0B | 2.0B | 1.7B |
Total Operating Expenses | 2.4B | 3.0B | 2.6B | 2.7B | 2.4B |
Operating Income | 1.1B | -2.0B | 331.6M | -298.3M | 2.8B |
Operating Margin % | 8.3% | -16.0% | 2.4% | -2.4% | 17.9% |
Non-Operating Items | |||||
Interest Income | - | 22.2M | 57.8M | 77.6M | 142.2M |
Interest Expense | 1.1B | 985.2M | 833.8M | 672.8M | 802.4M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 5.4M | -4.9B | -448.2M | -911.0M | 2.2B |
Income Tax | 0 | 785.4M | -225.7M | -328.1M | 1.5M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% |
Net Income | 5.4M | -5.7B | -222.5M | -582.9M | 2.2B |
Net Margin % | 0.0% | -45.8% | -1.6% | -4.7% | 14.0% |
Key Metrics | |||||
EBITDA | 2.1B | -972.1M | 1.5B | 923.0M | 4.1B |
EPS (Basic) | ₹0.14 | ₹-145.27 | ₹-5.68 | ₹-14.91 | ₹63.59 |
EPS (Diluted) | ₹0.14 | ₹-145.27 | ₹-5.68 | ₹-14.91 | ₹59.47 |
Basic Shares Outstanding | 38571429 | 39056736 | 39056736 | 38996581 | 34815790 |
Diluted Shares Outstanding | 38571429 | 39056736 | 39056736 | 38996581 | 34815790 |
Income Statement Trend
Solara Active Pharma Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 39.5M | 84.4M | 87.3M | 463.8M | 2.0B |
Short-term Investments | 125.2M | 75.8M | 133.9M | 104.0M | 286.2M |
Accounts Receivable | 3.3B | 3.5B | 5.4B | 4.9B | 4.8B |
Inventory | 3.2B | 3.6B | 5.6B | 5.8B | 2.9B |
Other Current Assets | 677.7M | 634.9M | 1.8M | 657.0M | 100.0K |
Total Current Assets | 7.3B | 8.0B | 11.9B | 12.4B | 10.6B |
Non-Current Assets | |||||
Property, Plant & Equipment | 8.0B | 8.5B | 9.2B | 9.0B | 9.1B |
Goodwill | 7.6B | 7.7B | 7.8B | 8.0B | 8.1B |
Intangible Assets | 298.0M | 425.6M | 543.5M | 679.4M | 799.8M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 71.2M | 52.8M | 100.7M | 315.5M | 483.8M |
Total Non-Current Assets | 15.0B | 15.5B | 17.1B | 17.1B | 15.6B |
Total Assets | 22.3B | 23.5B | 29.0B | 29.4B | 26.1B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 2.5B | 3.1B | 3.1B | 2.8B | 3.1B |
Short-term Debt | 6.6B | 8.9B | 7.7B | 7.4B | 4.5B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 109.1M | 160.3M | 50.0M | 54.0M | 50.3M |
Total Current Liabilities | 9.4B | 12.4B | 11.0B | 10.6B | 7.9B |
Non-Current Liabilities | |||||
Long-term Debt | 1.3B | 1.2B | 2.5B | 2.9B | 1.7B |
Deferred Tax Liabilities | - | - | - | - | 0 |
Other Non-Current Liabilities | 489.2M | 435.9M | 383.6M | 507.1M | 536.9M |
Total Non-Current Liabilities | 1.9B | 1.7B | 3.0B | 3.5B | 2.3B |
Total Liabilities | 11.3B | 14.1B | 14.0B | 14.2B | 10.2B |
Equity | |||||
Common Stock | 402.5M | 360.0M | 360.0M | 360.0M | 359.3M |
Retained Earnings | - | -3.2B | 2.5B | 2.7B | 3.4B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 11.0B | 9.4B | 15.0B | 15.3B | 15.9B |
Key Metrics | |||||
Total Debt | 8.0B | 10.1B | 10.1B | 10.4B | 6.2B |
Working Capital | -2.2B | -4.4B | 864.1M | 1.8B | 2.7B |
Balance Sheet Composition
Solara Active Pharma Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 5.4M | -4.9B | -448.2M | -911.0M | 2.2B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 26.8M | 6.0M | 500.0K | -13.1M | 51.4M |
Working Capital Changes | 624.5M | 1.8B | -381.6M | -2.9B | -3.0B |
Operating Cash Flow | 1.7B | -1.4B | -165.4M | -3.3B | -152.3M |
Investing Activities | |||||
Capital Expenditures | 3.8M | 10.4M | 13.0M | 1.3M | 29.7M |
Acquisitions | 9.6M | 0 | -12.8M | 0 | -1.0M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | 23.6M | 20.1M | 51.7M | 57.2M | 85.7M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | -107.8M | -197.3M |
Debt Issuance | 750.0M | 49.0M | 683.0M | 2.6B | 1.6B |
Debt Repayment | -1.1B | -1.2B | -1.3B | -937.6M | -2.6B |
Financing Cash Flow | -623.6M | -21.4M | -228.8M | 4.1B | 1.8B |
Free Cash Flow | 1.7B | 678.1M | 449.4M | -4.5B | -190.2M |
Net Change in Cash | 1.1B | -1.4B | -342.5M | 878.7M | 1.7B |
Cash Flow Trend
Solara Active Pharma Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
2,428.57
Price to Book
1.25
Price to Sales
1.65
PEG Ratio
-24.26
Profitability Ratios
Profit Margin
0.04%
Operating Margin
7.72%
Return on Equity
0.05%
Return on Assets
2.92%
Financial Health
Current Ratio
0.77
Debt to Equity
72.58
Beta
1.12
Per Share Data
EPS (TTM)
₹0.14
Book Value per Share
₹271.86
Revenue per Share
₹332.83
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
solarapp | 21.1B | 2,428.57 | 1.25 | 0.05% | 0.04% | 72.58 |
Sun Pharmaceutical | 3.8T | 36.63 | 5.27 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 68.71 | 10.59 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 46.3B | -13.52 | -21.31 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.6B | 23.66 | 3.26 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 42.0B | 195.40 | 5.96 | 4.35% | 1.41% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.